Search research articles
Contact Us
Filters
Showing results (91-100 of 129) with videos related to
Page
of 13
Sort By:
Investigational New Drugs
|
September 1, 2019
A Phase 1 study of BAL101553, a novel tumor checkpoint controller targeting microtubules, administered as 48-h infusion in adult patients with advanced solid tumors
Markus Joerger, Anastasios Stathis, Yannis Metaxas, et al.
BMC Cancer
|
September 11, 2019
Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: characteristics and survival data
Sabine Schmid, Dirk Klingbiel, Stefan Aebi, et al.
Melanoma Research
|
May 17, 2017
Multicenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland
Joanna Mangana, Phil F Cheng, Corina Kaufmann, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
September 3, 2015
Pain and analgesic use associated with skeletal-related events in patients with advanced cancer and bone metastases
Roger von Moos, Jean-Jacques Body, Blair Egerdie, et al.
Cancers
|
July 27, 2022
Real-World Evaluation of Quality of Life, Effectiveness, and Safety of Aflibercept Plus FOLFIRI in Patients with Metastatic Colorectal Cancer: The Prospective QoLiTrap Study
Ralf-Dieter Hofheinz, Sandro Anchisi, Birgit Grünberger, et al.
Swiss Medical Weekly
|
March 11, 2021
Patterns of care and economic consequences of using bone-targeted agents for castration-sensitive prostate cancer patients with bone metastases to prevent skeletal-related events in Switzerland - the SAKK 95/16 prostate study
Sandro Tiziano Stoffel, Roger von Moos, Beat Thürlimann, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
August 27, 2013
Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid
Roger von Moos, Jean-Jacques Body, Blair Egerdie, et al.
Cancer Chemotherapy and Pharmacology
|
August 25, 2019
Prospective, observational practice survey of applied skin care and management of cetuximab-related skin reactions: PROSKIN study
Sacha I Rothschild, Daniel Betticher, Reinhard Zenhäusern, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 15, 2012
Efficacy of cetuximab in metastatic castration-resistant prostate cancer might depend on EGFR and PTEN expression: results from a phase II trial (SAKK 08/07)
Richard Cathomas, Christian Rothermundt, Dirk Klingbiel, et al.
BMC Cancer
|
February 20, 2021
Quality of life and pain in patients with metastatic bone disease from solid tumors treated with bone-targeted agents- a real-world cross-sectional study from Switzerland (SAKK 95/16)
Karin Ribi, Beat Thürlimann, Corinne Schär, et al.
Page
of 13
Search research articles
Search
Showing results (91-100 of 129) with videos related to
Sort By:
Page
of 13
Investigational New Drugs
|
September 1, 2019
A Phase 1 study of BAL101553, a novel tumor checkpoint controller targeting microtubules, administered as 48-h infusion in adult patients with advanced solid tumors
Markus Joerger, Anastasios Stathis, Yannis Metaxas, et al.
BMC Cancer
|
September 11, 2019
Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: characteristics and survival data
Sabine Schmid, Dirk Klingbiel, Stefan Aebi, et al.
Melanoma Research
|
May 17, 2017
Multicenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland
Joanna Mangana, Phil F Cheng, Corina Kaufmann, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
September 3, 2015
Pain and analgesic use associated with skeletal-related events in patients with advanced cancer and bone metastases
Roger von Moos, Jean-Jacques Body, Blair Egerdie, et al.
Cancers
|
July 27, 2022
Real-World Evaluation of Quality of Life, Effectiveness, and Safety of Aflibercept Plus FOLFIRI in Patients with Metastatic Colorectal Cancer: The Prospective QoLiTrap Study
Ralf-Dieter Hofheinz, Sandro Anchisi, Birgit Grünberger, et al.
Swiss Medical Weekly
|
March 11, 2021
Patterns of care and economic consequences of using bone-targeted agents for castration-sensitive prostate cancer patients with bone metastases to prevent skeletal-related events in Switzerland - the SAKK 95/16 prostate study
Sandro Tiziano Stoffel, Roger von Moos, Beat Thürlimann, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
August 27, 2013
Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid
Roger von Moos, Jean-Jacques Body, Blair Egerdie, et al.
Cancer Chemotherapy and Pharmacology
|
August 25, 2019
Prospective, observational practice survey of applied skin care and management of cetuximab-related skin reactions: PROSKIN study
Sacha I Rothschild, Daniel Betticher, Reinhard Zenhäusern, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 15, 2012
Efficacy of cetuximab in metastatic castration-resistant prostate cancer might depend on EGFR and PTEN expression: results from a phase II trial (SAKK 08/07)
Richard Cathomas, Christian Rothermundt, Dirk Klingbiel, et al.
BMC Cancer
|
February 20, 2021
Quality of life and pain in patients with metastatic bone disease from solid tumors treated with bone-targeted agents- a real-world cross-sectional study from Switzerland (SAKK 95/16)
Karin Ribi, Beat Thürlimann, Corinne Schär, et al.
Page
of 13